Human α4β2 nicotinic acetylcholine receptor (α4β2 nAChR)

The **human α4β2 nicotinic acetylcholine receptor** is a pentameric ligand-gated ion channel composed primarily of alpha4 (CHRNA4) and beta2 (CHRNB2) subunits, forming the most abundant subtype of neuronal nicotinic receptors in the human brain[3][7][10]. It assembles as a heteropentamer in two primary stoichiometries, 2α:3β and 3α:2β, each with distinct pharmacological and biophysical properties[1][7]. It serves as the principal mediator of nicotine’s psychoactive effects and is central to cholinergic signaling in regions governing cognition, reward, and mood. The receptor is implicated in several CNS pathologies, including nicotine addiction, Parkinson’s disease, and epilepsy[2][3][8]. Drugs targeting α4β2 nAChR can act as agonists, partial agonists, or antagonists. The receptor is sensitive to modulation by endogenous and exogenous ligands, including nicotine, pharmaceutical agents like varenicline, and tobacco-specific nitrosamines[6][8]. It is pursued as a therapeutic target for nicotine dependence, movement disorders, and certain neuropsychiatric and neurodegenerative diseases because of its vital role in neurotransmitter release and neuronal excitability[3][8]. The receptor’s safety profile in drug development is complicated by risks of addiction, neurotoxicity, and the receptor’s propensity to desensitize and upregulate in response to chronic drug exposure or disease states[6][4].

Other names

α4β2 nAChRα4β2 nicotinic receptorNeuronal nicotinic acetylcholine receptor α4β2CHRNA4/CHRNB2 (referring to gene subunits alpha4 and beta2)Neuronal nAChR α4β2

Agonists mimic acetylcholine and open the receptor channel, depolarizing neurons Partial agonists activate receptor with less efficacy than acetylcholine/nicotine Antagonists block channel opening, preventing signal transduction Allosteric modulators may alter the channel’s response to agonists